1. Update on ABSORB EXTEND Study
Preliminary Data from ABSORB EXTEND: A Report of the 6-month Clinical Outcomes from the First 200 Patients Enrolled
Alexandre Abizaid, MD, PhD, FACC
Antonio L. Bartorelli MD; Robert Whitbourn MD; Lee Clark PhD; Bernard Chevalier MD; Karine Miquel-Hebert PhD; Xiaolin Li MS; Robert Jan Van Geuns MD, PhD; Didier Carrié MD, PhD; Pieter C. Smits MD, PhD; John A. Ormiston MBChB, PhD; Robert McGreevy PhD; Ashok Seth MD; Patrick W. Serruys MD, PhD
on behalf of the ABSORB EXTEND Investigators

2. Alexandre Abizaid, MD, PhD
Consulting Fees:
Abbott Vascular
BSC

3. Conflicts of Interest
Alexandre Abizaid; Instituto Dante Pazzanese, Sao Paulo, Brazil
Participation in the Advisory Board for Boston Scientific and Abbott Vascular.
Antonio L. Bartorelli; Centro Cardiologico Monzino, IRCCS, University of Milan, Milan, Italy
Participation in the Advisory Board for Abbott Vascular.
Robert Whitbourn MD; St. Vincent’s Hospital, Fitzroy, Australia
Lee Clark, Xiaolin Li, and Robert McGreevy; Abbott Vascular, Santa Clara, CA Karine Miquel-Hebert; Abbott Vascular, Diegem, Belgium
Employees of Abbott Vascular.
Bernard Chevalier; Institut Jacques Cartier, Massy, France
Consultant for Abbott Vascular, Biotronik, Terumo, and Medtronic. Recipient of research grant from Cordis.
Robert Jan Van Geuns; Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
No Conflicts of Interest
Didier Carrié; Hôpital Rangueil, Toulouse, France
Pieter C. Smits; Maasstad Ziekenhuis, Rotterdam, The Netherlands
Recipient of research grants from Cordis, Boston Scientific and Terumo. Recipient of travel and speaking fees from Abbott Vascular. A consultant for Blue Medical.
John A. Ormiston; Mercy Angiography, Mercy Hospital, Auckland, New Zealand
Participation in the Advisory Board for Abbott Vascular and Boston Scientific with minor honoraria.
Ashok Seth; Escorts Heart Institute and Research Centre, New Delhi, India
Participation in the Advisory Board for Abbott Vascular for BVS.
Patrick W. Serruys; Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands 3

4. The ABSORB Family of Trials
ABSORB EXTEND
5 year F/U*
2 year F/U**
Enrolling
Cohort A
Cohort B
EXTEND
Safety and Performance
Safety and Performance after assessing safety at 180 days in the Cohort A patients
Continuation of assessment of Safety and Performance
International
N=30
4 sites
International
N=101
12 sites
International
N  1,000
Up to 100 sites
Single de novo lesion
Up to two de novo lesions
Up to two de novo lesions, longer lesions, overlapping scaffolds
The ABSORB Trials are sponsored and funded by Abbott Vascular, Santa Clara, California
* 5-year clinical data from ABSORB Cohort A will be presented at AHA 2011
** 2-year clinical data from ABSORB Cohort B (Group 1) and 18 month data from the full cohort (Group 1 + 2) will be presented at TCT 2011 4

5. Background
Results from ABSORB Cohort A continue to be encouraging, with only 1 MACE and no scaffold thrombosis through 5 years of follow- up*.
The results from ABSORB Cohort B, performed with an ABSORB device with improved mechanical properties, confirm the performance and safety established in the Cohort A investigation:
The 12-month angiographic results from Cohort B (Group 1) demonstrated an in-segment late loss of 0.16 mm
MACE rate of 6.9% for the full cohort of 101 subjects at 12 months** (3 Non-Q wave MI, 4 ID-TLR)
No scaffold thrombosis events out to 12 months
* 5-year clinical data from ABSORB Cohort A will be presented at AHA 2011
** 2-year clinical data from ABSORB Cohort B (Group 1) and 18 month data from the full cohort (Group 1 + 2) will be presented at TCT 2011

6. ABSORB EXTEND Non-Randomized, Single-Arm, Continued Access Trial
30 d mo 12 mo 24 mo 36 mo
Clinical follow-up
MSCT follow-up (n=100)
OCT follow-up (n=50)
 1000 subjects Up to 100 International sites
Note: The ABSORB EXTEND Rev 3.0 protocol is currently pending approval.
*FPI: First Patient In
Study Objective:
Endpoints:
Continued Access trial. FPI*: Jan 11, 2010
No hypothesis-testing, typical PCI clinical endpoints
Treatment:
Up to 2 de novo lesions in different epicardial vessels Planned overlapping allowed in lesions >22 and ≤ 28 mm
Device Sizes:
Scaffold diameters: 2.5, 3.0 mm Scaffold lengths: 18, 28 mm

7. ABSORB EXTEND: Status as of Oct. 17, 2011
44 sites are open
397 patients are enrolled, shown by country
EMEA (198)
ANZ (53)
APJ (135) LA
(11)
Number enrolled 7

8. ABSORB EXTEND Trial Management
Principal Investigator: Alexandre Abizaid, MD, PhD; San Paulo, Brazil
Regional Co-Principal
Investigators: Antonio Bartorelli, MD; Milano, Italy;
Robert Whitbourn, MD; Fitzroy Victoria, Australia;
Chairman: Patrick W. Serruys, Prof, MD, PhD; Rotterdam, The Netherlands
Imaging Corelab: Cardialysis B.V.; Rotterdam, The Netherlands
CEC: Claude Hanet, MD, Ralph Tölg, MD, Angela Hoye, MD, Benno Rensing, MD, Karel Koch, MD, Eugene McFadden, MD, Vadim A. Kuznetsov, MD
DSMB: Jan G.P. Tijssen, PhD, Philip Urban, MD, Marcus
Wiemer, MD
Sponsor: Abbott Vascular

9. Key Inclusion & Exclusion Criteria
Up to two de novo lesions can be treated, each located in a separate native epicardial vessel
Target vessel diameter range is ≥ 2.0 mm and ≤ 3.3 mm
Target lesion length is ≤ 28 mm (planned overlapping allowed in lesions >22 and ≤ 28 mm)
Target lesion(s) meeting any of the following criteria are excluded:
Left main location;
Located within an arterial or saphenous vein graft or distal to a diseased arterial or saphenous vein graft;
Involves a bifurcation with a side branch  2 mm in diameter and ostial lesion > 40% stenosed or side branch requiring predilatation;
Total occlusion (TIMI flow 0), prior to wire crossing;
Excessive tortuosity proximal to or within the lesion;
Heavy calcification.

10. Quantitative Vessel Sizing - Online QCA
The recommended range for target vessel diameter is assessed in terms of the online QCA parameters distal Dmax and proximal Dmax, which refer to maximum lumen diameter evaluated at the distal and proximal ends of the target segment to be scaffolded, respectively.
Distal and proximal ends of target segment where Dmax is evaluated
Target Vessel Diameter Distal and Proximal
ABSORB BVS Diameter to be Used
≥ 2.0 mm and ≤ 3.0 mm
2.5 mm
≥ 2.5 mm and ≤ 3.3 mm
3.0 mm
Picture adapted from Site Initiation Visit Toolkit for ABSORB EXTEND.

11. Planned Overlap Proximal segment Distal segment Proximal: Post-implant
Pre-dil balloon markers
Proximal segment
Distal segment
Pre-dil balloon markers
Proximal: Post-implant
contrast
Post-dil balloon markers
Distal: Post-implant
contrast
Post-dil balloon markers

12. 6 Month Clinical Follow-up
(All Subjects Enrolled)
 Covers an enrollment period of January 11, 2010 to March 19, 2011
*F/U window ±14 days

13. Sites, Study Investigators, and Patient Enrollment (5 or more patients)
France, Bernard Chevalier 23
The Netherlands, Patrick Serruys 20
Australia, Robert Whitbourn 13
France, Didier Carrie 12
New Zealand, John Ormiston 11
The Netherlands, Pieter Smits
Israel, Ran Kornowski 9
Denmark, Leif Thuesen
Italy, Antonio Bartorelli 8
India, Tejas Patel
Switzerland, Stephan Windecker
Australia, Ian Meredith 7
India, Kuman Srineevas
Belgium, Bernard De Bruyne 6
India, Pravin Goel 5
New Zealand, Dougal McClean

14. ABSORB EXTEND - Baseline Demographics (All subjects enrolled)
Male (%)
74.0
Mean age (years)
62.4
Prior Cardiac Intervention on Target Vessel (%)
5.5
Previous MI (%)
27.5
Unstable Angina (%)
32.0
Diabetes mellitus (%)
21.5
Dyslipidemia req. med. (%)
65.0
Hypertension req. med. (%)
64.0
Current smoker (%)
18.5
Cohort B
(N = 101)
72.3
62.3
5.9
25.0
14.9
16.8
78.2
62.0
17.0

15. ABSORB EXTEND - Baseline Angiography (All subjects enrolled)
EXTEND (L = 213)
Lesion Location (%)
LAD
LCX
RCA
LMCA 39 33 28
0.5
QCA pre-procedure
RVD (mm)
MLD (mm)
% DS (%)
Proximal Dmax (mm)
Distal Dmax (mm)
2.58
1.03 60
2.81
2.67
Cohort B (L = 102) 43 23 33 1
2.61
1.06 59 NA
Note: L is the total number of target lesions.

16. ABSORB EXTEND – Lesion Characteristics (All subjects enrolled)
Angulation (≥ 45°)
Calcification (Moderate/Severe)
Eccentric
Thrombus 4 12 96
0.9
ACC/AHA Lesion Classification (%) A B1 B2 C 3 58 33 6
Lesion Length (mm)
Mean
Range (min, max)
11.42
(3.13, 24.86)
Cohort B
(L=102) 4 15 99 3 1 55 40 4
9.91
(2.92, 22.93)
Note: L is the total number of target lesions.

17. Procedural Parameters (All subjects enrolled)
EXTEND
(N=200)
(S=225)
Number of Target Lesions (%)
1 lesion subjects
93.0
2 lesion subjects
7.0
Planned Overlapping (%) – per subject
6.0
Bailout (%) – per subject
5.0
with BVS
2.0
metallic DES
3.0
Device Usage (%) – per scaffold
3.0 x 18 mm BVS
78.2
3.0 x 28 mm BVS
12.4
2.5 x 18 mm BVS
9.3
Cohort B
(N=101)
(S=225)
99.0
1.0 NA
4.0
0.0
100
Note: S is the total number of study scaffolds.

18. ABSORB EXTEND – Clinical Outcomes (All subjects enrolled)
Non-Hierarchical % (n)
30 Days
6 Months
(N=200)
Cardiac Death % (n)
0.0 (0)
0.5 (1) *
Myocardial Infarction % (n)
2.0 (4)
Q-wave MI
1.0 (2)
Non Q-wave MI
Ischemia driven TLR % (n)
0.5 (1)
CABG
PCI
Ischemia driven non-TL TVR % (n)
Hierarchical MACE % (n)
2.5 (5)
Hierarchical TVF % (n)
3.0 (6)
*A non-BVS was implanted in the target lesion. 18

19. Time Post Index Procedure (Days)
MACE Through 6 Months 5 10 30 60 90
120
150
180
210
240
2.5%
5.0%
Δ = 2.5%
194-day HR
1.99 [0.58,6.87]
p=0.27*
Cohort B
EXTEND
MACE (%)
Time Post Index Procedure (Days)
Number at risk
Time after index procedure (days) 37
194
Cohort B
101 99 96
EXTEND
200
195
* P-value is not from formal hypothesis testing and is displayed for descriptive purpose only.

20. Time Post Index Procedure (Days)
TVF Through 6 Months
Δ =2.0% 30 60 90
120
150
180
210
240
3.0%
5.0%
194-day HR
1.66 [0.51,5.44]
p=0.40*
TVF (%)
Time Post Index Procedure (Days)
Cohort B
EXTEND 5 10
Number at risk
Time after index procedure (days) 37
194
Cohort B
101 99 96
EXTEND
200
195
193
* P-value is not from formal hypothesis testing and is displayed for descriptive purpose only.

21. Time Post Index Procedure (Days)
MI Through 6 Months 30 60 90
120
150
180
210
240
Δ = 1.0%
2.0%
3.0%
194-day HR
1.49 [0.33, 6.65]
p=0.60*
MI (%)
Time Post Index Procedure (Days)
Cohort B
EXTEND 5 10
Number at risk
Time after index procedure (days) 37
194
Cohort B
101 99 98
EXTEND
200
195
* P-value is not from formal hypothesis testing and is displayed for descriptive purpose only.

22. Time Post Index Procedure (Days)
ID-TLR Through 6 Months 30 60 90
120
150
180
210
240
Δ = 1.5%
0.5%
2.0%
194-day HR
3.94 [0.36, 43.46]
p=0.23*
ID-TLR (%)
Time Post Index Procedure (Days)
Cohort B
EXTEND 5 10
Number at risk
Time after index procedure (days) 37
194
Cohort B
101 99
EXTEND
200
198
197
* P-value is not from formal hypothesis testing and is displayed for descriptive purpose only.

23. Time Post Index Procedure (Days)
ID-TVR Through 6 Months 30 60 90
120
150
180
210
240
Δ = 1.0%
1.0%
2.0%
194-day HR
1.97 [0.28, 13.99]
p=0.49*
ID-TVR (%)
Time Post Index Procedure (Days)
Cohort B
EXTEND 5 10
Number at risk
Time after index procedure (days) 37
194
Cohort B
101 99
EXTEND
200
198
196
* P-value is not from formal hypothesis testing and is displayed for descriptive purpose only.

24. Scaffold Thrombosis (ARC) through 6 Months (Definite/Probable)
ABSORB EXTEND
(N = 200)
Acute (<1 day)
- Definite
0.0% (0/200)
- Probable
- Definite/probable
Subacute (1-30 days)
0.5% (1/200)
Late (>30 days)
0.0% (0/199)
The overall definite/probable ST rate out to 194 days is 0.5%.

25. Conclusions
This snapshot of 200 subjects from ABSORB EXTEND included follow-up data out to 6 months.
Comparison of the ABSORB EXTEND subject demographics and lesion characteristics showed:
Longer mean lesion length than in ABSORB Cohort B
Planned overlapping treatment permitted (6.0% of subjects)
Over twice the percent of unstable angina subjects than in Cohort B
Based on 6 months outcomes in 200 subjects, the data showed:
Comparable MACE rates to ABSORB Cohort B
MACE rate driven primarily by MI events within 30 days post-procedure
Low rate of revascularization out to 6 months.
Despite an increase in complexity in ABSORB EXTEND, the data to date demonstrates the consistency in clinical outcomes between ABSORB EXTEND and ABSORB Cohort B.